Prexa Pharmaceuticals Secures $7,000,000 Series B Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=89bae812-37aa-43c5-af6e-6ef38d17daef&Preview=1 -
Date
5/11/2011 -
Company Name
Prexa Pharmaceuticals -
Mailing Address
184 High St. Boston, MA 02110 -
Company Description
Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinson’s disease. -
Website
http://www.prexainc.com -
Transaction Type
Venture Equity -
Transaction Amount
$7,000,000 -
Transaction Round
Series B -
Proceeds Purposes
Proceeds from the financing will allow thecompany to complete IND-enabling studies through Phase 1b clinical studies for its lead productcandidate PRX-12251. -
M&A Terms
-
Venture Investor
Advent Healthcare Ventures -
Venture Investor
Shire Pharmaceuticals -
Venture Investor
Undisclosed
